Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies
Citation
Tran , K T , McMenamin , Ú C , Hicks , B , Murchie , P , Thrift , A P , Coleman , H G , Iversen , L , Johnston , B T , Lee , A J & Cardwell , C R 2018 , ' Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies ' , Alimentary Pharmacology & Therapeutics , vol. 48 , no. 1 , pp. 55-64 . https://doi.org/10.1111/apt.14796
Rights
This is the peer reviewed version of the following article: Tran KT, McMenamin ÚC, Hicks B, et al. Proton pump inhibitor and histamine‐2 receptor antagonist use and risk of liver cancer in two population‐based studies. Aliment Pharmacol Ther. 2018;48:55–64., which has been published in final form at https://doi.org/10.1111/apt.14796. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.